Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Criscione SW, Martin MJ, Oien DB, Gorthi A, Miragaia RJ, Zhang J, Chen H, Karl DL, Mendler K, Markovets A, Gagrica S, Delpuech O, Dry JR, Grondine M, Hattersley MM, Urosevic J, Floc'h N, Drew L, Yao Y, Smith PD. Criscione SW, et al. Among authors: urosevic j. NPJ Precis Oncol. 2022 Dec 27;6(1):95. doi: 10.1038/s41698-022-00337-w. NPJ Precis Oncol. 2022. PMID: 36575215 Free PMC article.
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Bertran-Alamillo J, Giménez-Capitán A, Román R, Talbot S, Whiteley R, Floc'h N, Martínez-Pérez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino-Buslje C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar-Hernández A, Reguart N, Ditzel HJ, Martínez-Bueno A, Nabau-Moretó N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urosevic J, Molina-Vila MA. Bertran-Alamillo J, et al. Among authors: urosevic j. Mol Cancer. 2023 Jul 13;22(1):110. doi: 10.1186/s12943-023-01815-w. Mol Cancer. 2023. PMID: 37443114 Free PMC article.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D'Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, Sánchez-Guixé M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS. Lawson M, et al. Among authors: urosevic j. Cancer Res. 2023 Dec 1;83(23):3989-4004. doi: 10.1158/0008-5472.CAN-23-0694. Cancer Res. 2023. PMID: 37725704 Free PMC article.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: urosevic j. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, DeBruin E, Barry ST. Hopcroft L, et al. Among authors: urosevic j. NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6. NPJ Breast Cancer. 2023. PMID: 37596288 Free PMC article. No abstract available.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: urosevic j. NPJ Breast Cancer. 2023 Sep 19;9(1):76. doi: 10.1038/s41523-023-00581-8. NPJ Breast Cancer. 2023. PMID: 37726304 Free PMC article. No abstract available.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA. Ramkumar K, et al. Among authors: urosevic j. Clin Cancer Res. 2023 Aug 15;29(16):3237-3249. doi: 10.1158/1078-0432.CCR-23-0375. Clin Cancer Res. 2023. PMID: 37289191 Free PMC article.
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
Vasalou C, Proia TA, Kazlauskas L, Przybyla A, Sung M, Mamidi S, Maratea K, Griffin M, Sargeant R, Urosevic J, Rosenbaum AI, Yuan J, Aluri KC, Ramsden D, Hariparsad N, Jones RDO, Mettetal JT. Vasalou C, et al. Among authors: urosevic j. CPT Pharmacometrics Syst Pharmacol. 2024 Mar 26. doi: 10.1002/psp4.13133. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38532525 Free article.
Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.
Chou DB, Furlong BA, Posey RR, Kyprianou C, O'Sullivan LR, David R, Randle SJ, Polanska UM, Travers J, Urosevic J, Hutchinson JN, Che J, Howley AM, Hasserjian RP, Prantil-Baun R, Ingber DE. Chou DB, et al. Among authors: urosevic j. Nat Commun. 2022 Oct 12;13(1):6021. doi: 10.1038/s41467-022-33672-4. Nat Commun. 2022. PMID: 36224199 Free PMC article.
33 results